Compare Abeona Therapeutics Inc (ABEO) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Harley-Davidson Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Harley-Davidson Inc trades at $25.32 (market cap $2.73B). The key difference: Harley-Davidson Inc is far larger — about 7.3× Abeona Therapeutics Inc's market cap, and Harley-Davidson Inc pays a 2.84% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HOG | |
|---|---|---|
Market Cap | $373.32M | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $31.03 |
52-Week Low | $4.17 | $17.19 |
Enterprise Value | $228.22M | $3.12B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Harley-Davidson (HOG) trades at $25.89, up 3.73% today, with mixed technical signals showing bullish moving averages but neutral oscillators. Fundamentally, the company faces revenue declines from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 13.12 and P/B of 0.87. Recent Q1 2026 earnings missed expectations at $0.22 vs. $0.34, but Q2 results are anticipated on July 23, 2026. Positive developments include production returning to the US and cost-cutting initiatives.
The outlook is cautious with analyst consensus at Hold (65.71%) and price target of $23.20 below current price. Risks include ongoing margin pressure, competitive threats, and execution of turnaround plans. Upside potential exists if cost savings and US production boost profitability, but investors should monitor Q2 earnings for confirmation of operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
